Harmony Biosciences Holdings Inc (HRMY)
32.87
-0.62
(-1.85%)
USD |
NASDAQ |
Mar 28, 10:39
Harmony Biosciences Holdings Cash from Financing (TTM): -105.55M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -105.55M |
September 30, 2023 | -49.37M |
June 30, 2023 | 7.778M |
March 31, 2023 | 8.867M |
December 31, 2022 | 6.841M |
September 30, 2022 | 11.26M |
June 30, 2022 | 8.892M |
March 31, 2022 | 8.79M |
December 31, 2021 | 7.419M |
Date | Value |
---|---|
September 30, 2021 | -0.809M |
June 30, 2021 | 136.13M |
March 31, 2021 | 135.41M |
December 31, 2020 | 209.16M |
September 30, 2020 | 234.53M |
June 30, 2020 | 146.77M |
March 31, 2020 | 199.32M |
December 31, 2019 | 143.77M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-105.55M
Minimum
Dec 2023
234.53M
Maximum
Sep 2020
65.25M
Average
8.892M
Median
Jun 2022
Cash from Financing (TTM) Benchmarks
Intra-Cellular Therapies Inc | 17.81M |
Amylyx Pharmaceuticals Inc | 3.543M |
Arrowhead Pharmaceuticals Inc | 2.744M |
Exelixis Inc | -546.05M |
Inovio Pharmaceuticals Inc | 4.995M |